GlassScriptPhysician profile
Maureen Baxley
NPI 1407868276
$1,678.98
in general payments reported to CMS, 2019-2025
21 companies · $432 in 2025
The $432 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $76.13 · 2021: $185 · 2022: $211 · 2023: $265 · 2024: $380 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $304.62 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $168.43 | 2021-2025 | |
| Pfizer INC. | $163.79 | 2019-2024 | |
| Cranial Technologies, INC | $154.82 | 2019-2025 | Doc Band |
| Alk-Abello, INC | $140.50 | 2024-2025 | Ragwitek, Odactra, Grastek |
| Tris Pharma INC | $114.13 | 2021-2024 | Dyanavel Xr |
| Cumberland Pharmaceuticals, INC. | $95.14 | 2024-2025 | Kristalose |
| Corium, LLC | $94.95 | 2023-2025 | Azstarys |
| Kaleo, INC. | $69.21 | 2019-2024 | Auvi-Q |
| Seqirus USA INC | $68.81 | 2022-2025 | Flucelvax |
| Glaxosmithkline, LLC. | $62.52 | 2021-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $58.99 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $56.21 | 2021-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $18.48 | 2025 | |
| Collegium Pharmaceutical, INC. | $17.76 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $16.23 | 2025 | Neffy |
| Neos Therapeutics, LP | $15.90 | 2024 | Cotempla Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2023 | Flumist Quadrivalent |
| Ironshore Pharmaceuticals INC. | $14.75 | 2019 | |
| Adlon Therapeutics L.P. | $14.69 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Baxley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.